Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Applied Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on February 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 18, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding its clinical trial protocols, which created a false impression of compliance with good clinical practices [5]. - It is claimed that the company's failure to adhere to trial protocols posed a severe risk of rejection of trial data by the U.S. Food and Drug Administration (FDA) during the New Drug Application process [5].
APLT DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT